American Century Companies Inc. Acquires 2,165 Shares of Astera Labs, Inc. $ALAB

American Century Companies Inc. grew its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 46.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,783 shares of the company’s stock after purchasing an additional 2,165 shares during the quarter. American Century Companies Inc.’s holdings in Astera Labs were worth $405,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Astera Labs by 2,824.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 154,524 shares of the company’s stock worth $20,467,000 after buying an additional 149,240 shares in the last quarter. Aigen Investment Management LP raised its stake in Astera Labs by 50.9% in the first quarter. Aigen Investment Management LP now owns 17,920 shares of the company’s stock worth $1,069,000 after buying an additional 6,045 shares in the last quarter. Pacific Point Advisors LLC raised its stake in Astera Labs by 75.0% in the first quarter. Pacific Point Advisors LLC now owns 7,000 shares of the company’s stock worth $418,000 after buying an additional 3,000 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in Astera Labs by 73.6% in the first quarter. Oppenheimer Asset Management Inc. now owns 15,995 shares of the company’s stock worth $954,000 after buying an additional 6,783 shares in the last quarter. Finally, Taylor Frigon Capital Management LLC bought a new position in Astera Labs in the first quarter worth approximately $1,887,000. Institutional investors own 60.47% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Northland Securities lowered shares of Astera Labs from an “outperform” rating to a “market perform” rating and set a $120.00 price objective for the company. in a research note on Tuesday, July 22nd. Northland Capmk lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 22nd. Evercore ISI boosted their price objective on shares of Astera Labs from $104.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 6th. Barclays reiterated an “overweight” rating and set a $155.00 price objective (up previously from $75.00) on shares of Astera Labs in a research note on Thursday, August 7th. Finally, Morgan Stanley boosted their price objective on shares of Astera Labs from $155.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, August 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Astera Labs has a consensus rating of “Moderate Buy” and a consensus price target of $142.00.

Insider Transactions at Astera Labs

In other Astera Labs news, Director Jack R. Lazar sold 22,500 shares of the company’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $178.42, for a total value of $4,014,450.00. Following the completion of the transaction, the director owned 97,351 shares in the company, valued at approximately $17,369,365.42. This represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Manuel Alba sold 183,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $173.27, for a total transaction of $31,708,410.00. Following the completion of the transaction, the director owned 385,863 shares of the company’s stock, valued at approximately $66,858,482.01. This trade represents a 32.17% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,832,489 shares of company stock valued at $264,172,396. 12.50% of the stock is owned by corporate insiders.

Astera Labs Price Performance

Shares of ALAB opened at $191.20 on Friday. The firm has a market capitalization of $31.78 billion, a PE ratio of 341.43, a price-to-earnings-growth ratio of 4.85 and a beta of 1.48. Astera Labs, Inc. has a 1-year low of $36.85 and a 1-year high of $199.47. The company’s fifty day moving average price is $141.64 and its 200-day moving average price is $98.93.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. The firm had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business’s quarterly revenue was up 149.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.13 earnings per share. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, research analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.